213 related articles for article (PubMed ID: 21445077)
21. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic changes in therapy-related MDS/AML.
Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
[TBL] [Abstract][Full Text] [Related]
23. Familial myelodysplastic syndrome/acute myeloid leukemia.
Churpek JE
Best Pract Res Clin Haematol; 2017 Dec; 30(4):287-289. PubMed ID: 29156196
[TBL] [Abstract][Full Text] [Related]
24. ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events.
Haferlach C; Bacher U; Schnittger S; Alpermann T; Zenger M; Kern W; Haferlach T
Genes Chromosomes Cancer; 2012 Apr; 51(4):328-37. PubMed ID: 22162288
[TBL] [Abstract][Full Text] [Related]
25. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms.
Schnittger S; Bacher U; Haferlach C; Alpermann T; Dicker F; Sundermann J; Kern W; Haferlach T
Leukemia; 2011 Apr; 25(4):615-21. PubMed ID: 21233837
[TBL] [Abstract][Full Text] [Related]
26. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.
Benetatos L; Dasoula A; Hatzimichael E; Syed N; Voukelatou M; Dranitsaris G; Bourantas KL; Crook T
Ann Hematol; 2011 Sep; 90(9):1037-45. PubMed ID: 21340720
[TBL] [Abstract][Full Text] [Related]
27. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling in acute myeloid leukaemia (AML).
Bacher U; Kohlmann A; Haferlach C; Haferlach T
Best Pract Res Clin Haematol; 2009 Jun; 22(2):169-80. PubMed ID: 19698926
[TBL] [Abstract][Full Text] [Related]
29. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
30. AML1/RUNX1 gene point mutations in childhood myeloid malignancies.
Migas A; Savva N; Mishkova O; Aleinikova OV
Pediatr Blood Cancer; 2011 Oct; 57(4):583-7. PubMed ID: 21294243
[TBL] [Abstract][Full Text] [Related]
31. Molecular cytogenetic profiling of complex karyotypes in primary myelodysplastic syndromes and acute myeloid leukemia.
Trost D; Hildebrandt B; Beier M; Müller N; Germing U; Royer-Pokora B
Cancer Genet Cytogenet; 2006 Feb; 165(1):51-63. PubMed ID: 16490597
[TBL] [Abstract][Full Text] [Related]
32. AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes.
Zatkova A; Merk S; Wendehack M; Bilban M; Muzik EM; Muradyan A; Haferlach C; Haferlach T; Wimmer K; Fonatsch C; Ullmann R
Genes Chromosomes Cancer; 2009 Jun; 48(6):510-20. PubMed ID: 19306356
[TBL] [Abstract][Full Text] [Related]
33. Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses.
Braoudaki M; Tzortzatou-Stathopoulou F; Anagnostopoulos AK; Papathanassiou C; Vougas K; Karamolegou K; Tsangaris GT
Amino Acids; 2011 Mar; 40(3):943-51. PubMed ID: 20711619
[TBL] [Abstract][Full Text] [Related]
34. Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies.
Morrissette JJ; Bagg A
Clin Lab Med; 2011 Dec; 31(4):659-86, x. PubMed ID: 22118743
[TBL] [Abstract][Full Text] [Related]
35. Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
Tawana K; Drazer MW; Churpek JE
Leukemia; 2018 Jul; 32(7):1482-1492. PubMed ID: 29483711
[TBL] [Abstract][Full Text] [Related]
36. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
37. Gene stage-specific expression in the microenvironment of pediatric myelodysplastic syndromes.
Roela RA; Carraro DM; Brentani HP; Kaiano JH; Simão DF; Guarnieiro R; Lopes LF; Borojevic R; Brentani MM
Leuk Res; 2007 May; 31(5):579-89. PubMed ID: 17092558
[TBL] [Abstract][Full Text] [Related]
38. Expression profiling of leukemia patients: key lessons and future directions.
Shivarov V; Bullinger L
Exp Hematol; 2014 Aug; 42(8):651-60. PubMed ID: 24746875
[TBL] [Abstract][Full Text] [Related]
39. Current status of gene expression profiling in the diagnosis and management of acute leukaemia.
Bacher U; Kohlmann A; Haferlach T
Br J Haematol; 2009 Jun; 145(5):555-68. PubMed ID: 19344393
[TBL] [Abstract][Full Text] [Related]
40. Genetic classification of acute myeloid leukemia (AML).
Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
Ann Hematol; 2004; 83 Suppl 1():S97-100. PubMed ID: 15124693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
